Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes

被引：0
|
作者：
Yuan, Peng
Wang, Jiayu
Ma, Fei
Fan, Ying
Luo, Yang
Cai, Ruigang
Zhang, Pin
Li, Qing
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
[4] Chinese Acad Med, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.
    Yuan, Peng
    Du, Feng
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
    Shulman, Lawrence N.
    Cirrincione, Constance T.
    Berry, Donald A.
    Becker, Heather P.
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Atkins, James N.
    Mayer, Erica
    Schneider, Charles J.
    Kimmick, Gretchen
    Norton, Larry
    Muss, Hyman
    Winer, Eric P.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4071 - 4076
  • [3] Adjuvant four cycles of epirubicin and cyclophosphamide with radiation therapy in operated stage II-III breast cancer
    Unsal, M
    Yoney, A
    Erman, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 76 - 76
  • [4] Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer
    Roy, C.
    Choudhury, K. B.
    Pal, M.
    Saha, A.
    Bag, S.
    Banerjee, C.
    INDIAN JOURNAL OF CANCER, 2012, 49 (03) : 266 - 271
  • [5] West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
    Nitz, Ulrike
    Gluz, Oleg
    Clemens, Michael
    Malter, Wolfram
    Reimer, Toralf
    Nuding, Benno
    Aktas, Bahriye
    Stefek, Andrea
    Pollmanns, Anke
    Lorenz-Salehi, Fatemeh
    Uleer, Christoph
    Krabisch, Petra
    Kuemmel, Sherko
    Liedtke, Cornelia
    Shak, Steven
    Wuerstlein, Rachel
    Christgen, Matthias
    Kates, Ronald E.
    Kreipe, Hans H.
    Harbeck, Nadia
    Ackermann, S.
    Aktas, B.
    Augustin, D.
    Baake, G.
    Baumann, K.
    Berger, R.
    Bettscheider, J.
    Bischoff, J.
    Clemens, M.
    Deryal, M.
    Dubbers, H.
    Duchting, D.
    Dunnebacke, J.
    Fett, W.
    Fietz, T.
    Fischer, H.
    Forner, M.
    Forstbauer, H.
    Freese, K.
    Geberth, M.
    Glados, M.
    Gnauert, K.
    Goette, O.
    Gohring, U.
    Goppinger, A.
    Grafe, A.
    Hackenberg, R.
    Hackmann, J.
    Hellriegel, M.
    Heyl, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (10) : 799 - +
  • [6] Sequential dose-dense epirubicin/paclitaxel (E-T) with G-CSF support compared to standard EC-T (epirubicin/cyclophosphamide followed by paclitaxel) for patients with operable breast cancer and 1-3 positive lymph nodes - first toxicity analysis.
    Eggemann, H
    Krocker, J
    Kuemmel, S
    Ulm, K
    Zeiser, T
    Kreienberg, R
    Budner, M
    Lichtenegger, W
    Renziehausen, K
    Koelbl, H
    Kohls, A
    Morack, G
    Koehler, U
    Emons, G
    Breitbach, GP
    Elling, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S159 - S159
  • [7] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
    Boccardo, Francesco
    Amadori, Dino
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    ONCOLOGY, 2010, 78 (3-4) : 274 - 281
  • [8] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in patients with operable breast cancer and ≥10 positive axillary nodes
    Fountzilas, G
    Dimopoulos, M
    Papadimitriou, C
    Aravantinos, G
    Briassoulis, E
    Bafaloukos, D
    Papakostas, P
    Pavlidis, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 179 - 179
  • [9] Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes:: vinorelbine plus epirubicin;: vinorelbine plus epirubicin sequential followed up by paclitaxel;: epirubicin plus cyclophosphamide;: epirubicin plus cyclophosphamide sequential followed up by paclitaxel.: A phase II study
    Elling, D
    Eggemann, H
    Kümmel, S
    Breitbach, P
    Kohls, A
    Morack, G
    Schlosser, H
    Krocker, J
    BREAST, 2003, 12 (03): : 208 - 211
  • [10] Four versus six cycles of docetaxel and cyclophosphamide in early breast cancer.
    Basu, Aparna
    Dabak, Vrushali S.
    Loutfi, Randa
    Ali, Haythem Y.
    Mohammed, Hadi
    Mahmood, Sharmeen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345